Business Description
Zealand Pharma AS
ISIN : DK0060257814
Compare
Compare
Traded in other countries / regions
ZEAL.Denmark0NZU.UKZLDPF.USA22Z.Germany IPO Date
2011-10-27Description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.75 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.41 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 43.3 | |||||
| Beneish M-Score | -1.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.6 | |||||
| 3-Year EBITDA Growth Rate | 10.7 | |||||
| 3-Year EPS without NRI Growth Rate | 16.8 | |||||
| 3-Year FCF Growth Rate | 24.7 | |||||
| 3-Year Book Growth Rate | -4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 143.95 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.15 | |||||
| 9-Day RSI | 68.3 | |||||
| 14-Day RSI | 58.81 | |||||
| 3-1 Month Momentum % | -8.13 | |||||
| 6-1 Month Momentum % | 34.28 | |||||
| 12-1 Month Momentum % | 150.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 35.49 | |||||
| Quick Ratio | 35.49 | |||||
| Cash Ratio | 34.49 | |||||
| Days Inventory | 78.75 | |||||
| Days Sales Outstanding | 469.3 | |||||
| Days Payable | 4174.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | -15.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.06 | |||||
| Operating Margin % | -1471.82 | |||||
| Net Margin % | -1369.25 | |||||
| FCF Margin % | -932.16 | |||||
| ROE % | -21.46 | |||||
| ROA % | -19.12 | |||||
| ROIC % | -146.21 | |||||
| 3-Year ROIIC % | -12.83 | |||||
| ROC (Joel Greenblatt) % | -252.46 | |||||
| ROCE % | -18.77 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 620.62 | |||||
| PB Ratio | 6.57 | |||||
| Price-to-Tangible-Book | 6.58 | |||||
| EV-to-EBIT | -44.59 | |||||
| EV-to-EBITDA | -45.9 | |||||
| EV-to-Revenue | 574.27 | |||||
| EV-to-FCF | -64.61 | |||||
| Price-to-GF-Value | 6.45 | |||||
| Price-to-Net-Current-Asset-Value | 7.32 | |||||
| Price-to-Net-Cash | 7.56 | |||||
| Earnings Yield (Greenblatt) % | -2.24 | |||||
| FCF Yield % | -1.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZLDPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zealand Pharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11.18 | ||
| EPS (TTM) ($) | -2.449 | ||
| Beta | 0.78 | ||
| 3-Year Sharpe Ratio | 1.08 | ||
| 3-Year Sortino Ratio | 2.34 | ||
| Volatility % | 61.72 | ||
| 14-Day RSI | 58.81 | ||
| 14-Day ATR ($) | 3.062929 | ||
| 20-Day SMA ($) | 103.54745 | ||
| 12-1 Month Momentum % | 150.72 | ||
| 52-Week Range ($) | 50.65 - 141.742 | ||
| Shares Outstanding (Mil) | 70.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zealand Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zealand Pharma AS Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zealand Pharma AS Frequently Asked Questions
What is Zealand Pharma AS(ZLDPF)'s stock price today?
The current price of ZLDPF is $114.49. The 52 week high of ZLDPF is $141.74 and 52 week low is $50.65.
When is next earnings date of Zealand Pharma AS(ZLDPF)?
The next earnings date of Zealand Pharma AS(ZLDPF) is 2025-02-20.
Does Zealand Pharma AS(ZLDPF) pay dividends? If so, how much?
Zealand Pharma AS(ZLDPF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers